The working mechanism of BRD4 PROTAC and fulvestrant was investigated through GREB1 signaling disruption.<h4>Results</h4>The occupancy of BRD4 at promoter regions was found to be increased in breast cancer, and its high expression indicated poor clinical outcome among ER+ breast cancer patients with endocrine therapy. The gene discussed is ESR1; the disease is breast carcinoma.